PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Renal Cell; Lymphoma, T-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms

Treatments: Drug: PF-3512676

Study type: Interventional

Funder types: Industry

Identifiers

NCT00043368

C016

CO16, A8501015

Details and patient eligibility

About

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.

Exclusion criteria

The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

31 participants in 1 patient group

1

Experimental group

Description:

Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.

Treatment:

Drug: PF-3512676